(Q85179303)

English

Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine

scientific article published on October 28, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

therapeutic vaccine

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Xuan-Yi Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Xin-Xin Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Xin Yao

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Jie-Hong Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

You-Hua Xie

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Zheng-Hong Yuan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Yu-Mei Wen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20937312

31 July 2024

publication date

28 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10014350?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.09.093

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.093

31 July 2024

https://api.elsevier.com/content/article/PII:S0264410X10014350?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.09.093

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.093

31 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

51

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

8169-8174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Side effects of long-term oral antiviral therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Antiviral resistance and hepatitis B therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Therapeutic vaccines for chronic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Towards immunotherapy for chronic hepatitis B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Vaccination with recombinant HBsAg-HBIG complex in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Therapeutic vaccination in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Progress in DNA vaccine for prophylaxis and therapy of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Immunomodulatory therapy for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Therapeutic vaccination in chronic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Chronic hepatitis B: back to the future with HBsAg

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Therapy of hepatitis B -- viral suppression or eradication?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.093

7 January 2021

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

27

1 reference

10.1016/J.VACCINE.2010.09.093

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.093

31 July 2024

Identifiers

10.1016/J.VACCINE.2010.09.093

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20937312%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85179303&oldid=2216998004"